Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays.

To explore molecular mechanisms of prostate cancer progression, we applied tissue microarrays (TMAs) to analyze expression of candidate gene targets discovered by cDNA microarray analysis of the CWR22 xenograft model system. A TMA with 544 clinical specimens from different stages of disease progression was probed by mRNA in situ hybridization and protein immunohistochemistry. There was an excellent correlation (r = 0.96; n = 16) between the expression levels of the genes in the xenografts by cDNA microarray and mRNA in situ hybridization on a TMA. One of the most highly overexpressed genes in hormone-refractory CWR22R xenografts was the S100P gene. This gene, coding for a calcium signaling molecule implicated in the loss of senescence, was also significantly associated with progression in clinical tumors by TMA analysis (P < 0.001), suggesting dysregulation of this pathway in hormone-refractory and metastatic prostate cancers. Conversely, two genes that were down-regulated during tumor progression in the CWR22 model system were validated in vivo: crystallin mu (CRYM) and a LIM-domain protein LMO4 both showed significantly lower mRNA levels in hormone-refractory tumors as compared with primary tumors (P < 0.001). These results illustrate a strategy for rapid clinical validation at the mRNA and protein level of gene targets found to be differentially expressed in cDNA microarray experiments of model systems of cancer.

[1]  O. Kallioniemi,et al.  Clinical and functional target validation using tissue and cell microarrays. , 2002, Current opinion in chemical biology.

[2]  G. Makhatadze,et al.  Oligomerization and divalent ion binding properties of the S100P protein: a Ca2+/Mg2+-switch model. , 1998, Journal of molecular biology.

[3]  M. Resnick,et al.  Xenografts of primary human prostatic carcinoma. , 1993, Journal of the National Cancer Institute.

[4]  P. Kantoff,et al.  Regulation of S100P expression by androgen , 1996, The Prostate.

[5]  S. Schwartz,et al.  CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. , 1996, Cancer research.

[6]  G. Wistow,et al.  mu-crystallin is a mammalian homologue of Agrobacterium ornithine cyclodeaminase and is expressed in human retina. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[7]  E Mahlamäki,et al.  Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. , 1999, Journal of the National Cancer Institute.

[8]  O. Kallioniemi,et al.  Tissue microarray technology for high-throughput molecular profiling of cancer. , 2001, Human molecular genetics.

[9]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[10]  W. V. van Weerden,et al.  Use of nude mouse xenograft models in prostate cancer research , 2000, The Prostate.

[11]  M. Kneba,et al.  Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin‐resistant cell lines: comparison of mRNA differential display reverse transcription‐polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression , 1998, Anti-cancer drugs.

[12]  Spyro Mousses,et al.  Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling , 2001, Oncogene.

[13]  T. Pretlow,et al.  CWR22 xenograft as an ex vivo human tumor model for prostate cancer gene therapy. , 1996, Journal of the National Cancer Institute.

[14]  M. Ito,et al.  mu-Crystallin, thyroid hormone-binding protein, is expressed abundantly in the murine inner root sheath cells. , 2000, The Journal of investigative dermatology.

[15]  Y. Chen,et al.  Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. , 2000, Journal of the National Cancer Institute.

[16]  J. Russo,et al.  S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo. , 2000, International journal of oncology.

[17]  F. Peale,et al.  Detection of novel gene expression in paraffin‐embedded tissues by isotopic in situ hybridization in tissue microarrays , 2001, The Journal of pathology.

[18]  L. Sapinoso,et al.  Functional dissection of transcriptional profiles in androgen-dependent and -independent prostate cancer , 2001, Nature Genetics.

[19]  N. Carter,et al.  Characterization of the Lmo4 gene encoding a LIM-only protein: genomic organization and comparative chromosomal mapping , 1999, Mammalian Genome.

[20]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[21]  W. E. Gye,et al.  CANCER RESEARCH , 1923, British medical journal.

[22]  J. Isaacs,et al.  The biology of hormone refractory prostate cancer. Why does it develop? , 1999, The Urologic clinics of North America.

[23]  G. Makhatadze,et al.  Cloning, overexpression, purification, and spectroscopic characterization of human S100P , 1998, Protein science : a publication of the Protein Society.

[24]  Y. Saga,et al.  Identification and characterization of LMO4, an LMO gene with a novel pattern of expression during embryogenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Schwartz,et al.  CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. , 1994, Cancer research.